A great number of psoriasis patients go untreated with an average diagnosis time of five years according to a new study conducted by the Technical University of Munich, Germany. The Problem—Psoriasis Psoriasis is a common, noncommunicable skin disease with at least...
Dutch researchers from Radboud University Medical Center collaborated with TropIQ, a Nijmegen-based spin-off and other researchers report that a molecule once designed to cure the skin disease psoriasis appears to be particularly effective against malaria—the...
Angeles Hospital, a private state-of-the-art hospital in Tijuana, Mexico is conducting a clinical trial on behalf of Irvine, CA biotech sponsor NKMax America (part of Korean Parent) and just announced it treated the first participant in the study of SNK01-MX03, a...
We had several requests from our Hidradenitis Suppurativa readers to do a follow up on the article “Is XBiotech on the Cusp of a Superior Hidradenitis Suppurativa Treatment?” So we asked XBiotech if they would be willing to sit down and talk with us about...
Janssen reveals positive top-line results from two phase 3 trials of Tremfya (guselkumab) in patients with moderate to severe arthritis (PsA). Guselkumab is a human monoclonal antibody that blocks the p19 subunit of interleukin (IL)-23. The DISCOVER-1 (N=381) and...
A team of Seoul St. Mary’s Hospital investigators utilizing population health data, involving over 1 million patients over 10 years, found evidence of a 2X increase of mental health disorders associated with psoriasis. These mental health issues include: Depressive...
